Skip to main content

Articles

Page 9 of 66

  1. Chronic migraine places a disabling burden on patients, which is extensively modeled by the nitroglycerin (NTG)-treated animal model. Although the NF-κB pathway is involved in an increase in CGRP levels and ac...

    Authors: Hao Chen, Xueqian Tang, Jin Li, Bangyan Hu, Wenqin Yang, Meng Zhan, Tengyun Ma and Shijun Xu
    Citation: The Journal of Headache and Pain 2022 23:1
    Content type: Research article Published on:

  2. Migraine preventive treatment with CGRP(−receptor) monoclonal antibodies (mAbs) has a positive effect on patients’ health-related quality of life (HRQoL). The German treatment guidelines recommend discontinuin...

    Authors: Maria Terhart, Jasper Mecklenburg, Lars Neeb, Lucas Hendrik Overeem, Anke Siebert, Maureen Steinicke, Bianca Raffaelli and Uwe Reuter
    Citation: The Journal of Headache and Pain 2021 22:158
    Content type: Research article Published on:

  4. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness...

    Authors: Peter McAllister, Lois Lamerato, Lynda J. Krasenbaum, Joshua M. Cohen, Krishna Tangirala, Stephen Thompson, Maurice Driessen, Julian Casciano, Zenobia Dotiwala and Alexander Mauskop
    Citation: The Journal of Headache and Pain 2021 22:156
    Content type: Research article Published on:

  5. The purpose of this narrative review is to examine the literature investigating a causal relationship between stress and migraine and evaluate its implications for managing migraine.

    Authors: Anker Stubberud, Dawn C. Buse, Espen Saxhaug Kristoffersen, Mattias Linde and Erling Tronvik
    Citation: The Journal of Headache and Pain 2021 22:155
    Content type: Review article Published on:

  6. Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their ...

    Authors: Fabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, Carmelina Maria Costa, Bruno Colombo, Paola Torelli, Simone Quintana, Sabina Cevoli, Valentina Favoni, Florindo d’Onofrio, Gabriella Egeo, Renata Rao, Massimo Filippi, Piero Barbanti and Claudia Altamura
    Citation: The Journal of Headache and Pain 2021 22:154
    Content type: Research article Published on:

  7. Headache disorders are disabling, with major consequences for productivity, yet the literature is silent on the relationship between headache-attributed disability and lost productivity, often erroneously rega...

    Authors: Hallie Thomas, Simple Futarmal Kothari, Andreas Husøy, Rigmor Højland Jensen, Zaza Katsarava, Michela Tinelli and Timothy J. Steiner
    Citation: The Journal of Headache and Pain 2021 22:153
    Content type: Research article Published on:

  8. Migraine prevalence is age and sex dependent, predominating in women in early and middle adulthood; however, migraine also represents a substantial burden for men and adults of all ages. Thus, understanding th...

    Authors: Antoinette MaassenVanDenBrink, Gisela M. Terwindt, Joshua M. Cohen, Steve Barash, Verena Ramirez Campos, Maja Galic, Xiaoping Ning and Mikko Kärppä
    Citation: The Journal of Headache and Pain 2021 22:152
    Content type: Research article Published on:

  9. Patient-Reported Outcomes (PROs) have been developed to numerically quantify disability, impact and quality of life. They have been widely used in migraine clinical trials. However, we still do not know which ...

    Authors: Alicia Alpuente, Victor J Gallardo, Edoardo Caronna, Marta Torres-Ferrus and Patricia Pozo-Rosich
    Citation: The Journal of Headache and Pain 2021 22:151
    Content type: Research article Published on:

  10. An imbalance between inhibitory and excitatory neurometabolites has been implicated in chronic pain. Prior work identified elevated levels of Gamma-aminobutyric acid + macromolecules (“GABA+”) using magnetic r...

    Authors: Aimie L. Peek, Andrew M. Leaver, Sheryl Foster, Nicolaas A. Puts, Georg Oeltzschner, Luke Henderson, Graham Galloway, Karl Ng, Kathryn Refshauge and Trudy Rebbeck
    Citation: The Journal of Headache and Pain 2021 22:150
    Content type: Research article Published on:

  11. Calcitonin gene-related peptide ligand/receptor (CGRP) antibodies effectively reduce headache frequency in migraine. It is understood that they act peripherally, which raises the question whether treatment mer...

    Authors: Anne Thiele, Lara Klehr, Sebastian Strauß, Anselm Angermaier, Ulf Schminke, Martin Kronenbuerger, Steffen Naegel and Robert Fleischmann
    Citation: The Journal of Headache and Pain 2021 22:149
    Content type: Research article Published on:

  12. Patients with visual snow syndrome (VSS) suffer from a debilitating continuous (“TV noise-like”) visual disturbance. They report problems with vision at night and palinopsia despite normal visual acuity. The u...

    Authors: Ozan E. Eren, Andreas Straube, Florian Schöberl, Ruth Ruscheweyh, Thomas Eggert and Christoph J. Schankin
    Citation: The Journal of Headache and Pain 2021 22:148
    Content type: Research article Published on:

  13. Accumulating studies have indicated a wide range of brain alterations with respect to the structure and function of classic trigeminal neuralgia (CTN). Given the dynamic nature of pain experience, the explorat...

    Authors: Pengfei Zhang, Yanli Jiang, Guangyao Liu, Jiao Han, Jun Wang, Laiyang Ma, Wanjun Hu and Jing Zhang
    Citation: The Journal of Headache and Pain 2021 22:147
    Content type: Research article Published on:

  14. Purinergic P2X7 receptor plays an important role in migraine pathophysiology. Yet precise molecular mechanism underlying P2X7R signaling in migraine remains unclear. This study explores the hypothesis that P2X...

    Authors: Lingdi Nie, Dongqing Ma, John P. Quinn and Minyan Wang
    Citation: The Journal of Headache and Pain 2021 22:146
    Content type: Research article Published on:

  15. Migraine represents one of the most prevalent neurological conditions worldwide. It is a disabling condition with high impact on the working situation of migraineurs. Interestingly, gender-related differences ...

    Authors: Oreste Affatato, Maud Miguet, Helgi B. Schiöth and Jessica Mwinyi
    Citation: The Journal of Headache and Pain 2021 22:145
    Content type: Research article Published on:

  16. Transcranial direct current stimulation (tDCS) could counteract the pathophysiological triggers of migraine attacks by modulating cortical excitability. Several pilot randomized controlled trials (RCTs) assess...

    Authors: Raffaele Ornello, Valeria Caponnetto, Susanna Ratti, Giulia D’Aurizio, Chiara Rosignoli, Francesca Pistoia, Michele Ferrara, Simona Sacco and Aurora D’Atri
    Citation: The Journal of Headache and Pain 2021 22:144
    Content type: Review article Published on:

  17. Patients with migraine have an increased relative risk of cardio- and cerebrovascular events, and some migraine treatments may exacerbate this risk. The primary objective of this analysis was to determine whet...

    Authors: Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Anders Ettrup and Vivienne Shen
    Citation: The Journal of Headache and Pain 2021 22:143
    Content type: Research article Published on:

  18. Migraine is a common brain disorder but reliable diagnostic biomarkers in blood are still lacking. Our aim was to identify, using proton nuclear magnetic resonance (1H-NMR) spectroscopy, metabolites in serum that...

    Authors: Aster V. E. Harder, Lisanne S. Vijfhuizen, Peter Henneman, Ko Willems van Dijk, Cornelia M. van Duijn, Gisela M. Terwindt and Arn M. J. M. van den Maagdenberg
    Citation: The Journal of Headache and Pain 2021 22:142
    Content type: Research article Published on:

  19. Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy. Additionally, evi...

    Authors: Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow and Christian Lampl
    Citation: The Journal of Headache and Pain 2021 22:141
    Content type: Research article Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:57

  20. Health care costs of migraine constitute a major issue in health economics. Several publications analyzed health care costs for adult migraine patients, based on questionnaires or secondary (health insurance) ...

    Authors: Viola Obermeier, Monika Murawski, Florian Heinen, Mirjam N. Landgraf, Andreas Straube, Rüdiger von Kries and Ruth Ruscheweyh
    Citation: The Journal of Headache and Pain 2021 22:140
    Content type: Research article Published on:

  21. Occipital transcranial direct current stimulation (tDCS) is an effective and safe treatment for migraine attack prevention. Structural brain alterations have been found in migraineurs in regions related to pai...

    Authors: Simon Schading, Heiko Pohl, Andreas Gantenbein, Roger Luechinger, Peter Sandor, Franz Riederer, Patrick Freund and Lars Michels
    Citation: The Journal of Headache and Pain 2021 22:139
    Content type: Research article Published on:

  22. Pain is generally concomitant with an inflammatory reaction at the site where the nociceptive fibers are activated. Rodent studies suggest that a sterile meningeal inflammatory signaling cascade may play a rol...

    Authors: Şefik Evren Erdener, Zeynep Kaya and Turgay Dalkara
    Citation: The Journal of Headache and Pain 2021 22:138
    Content type: Review article Published on:

  24. Post-traumatic headache (PTH) is a very common symptom following mild traumatic brain injury (mTBI), yet much remains unknown about the underlying pathophysiological mechanisms of PTH. Neuroimaging studies sug...

    Authors: Fengfang Li, Liyan Lu, Song’an Shang, Huiyou Chen, Peng Wang, Vijaya Prakash Muthaiah, Xindao Yin and Yu-Chen Chen
    Citation: The Journal of Headache and Pain 2021 22:137
    Content type: Research article Published on:

  25. General practitioners (GPs) diagnose and manage a majority of headache patients seeking health care. With the aim to understand the potential for clinical improvement and educational needs, we performed a stud...

    Authors: Espen Saxhaug Kristoffersen, Kashif Waqar Faiz, Jakob Møller Hansen, Erling Andreas Tronvik, Jan C. Frich, Christofer Lundqvist and Bendik Slagsvold Winsvold
    Citation: The Journal of Headache and Pain 2021 22:136
    Content type: Research article Published on:

  27. Headache affects 90–99% of the population. Based on the question “Do you think that you never ever in your whole life have had a headache?” 4% of the population say that they have never experienced a headache....

    Authors: Isa Amalie Olofsson, Jeppe Hvedstrup, Katrine Falkenberg, Mona Ameri Chalmer, Henrik Winther Schytz, Miguel Benjamin Pedersen, Henrik Ullum, Ole Birger Pedersen, Jes Olesen and Thomas Folkmann Hansen
    Citation: The Journal of Headache and Pain 2021 22:134
    Content type: Research article Published on:

  28. Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in...

    Authors: Andreas Straube, Philipp Stude, Charly Gaul, Katrin Schuh and Mirja Koch
    Citation: The Journal of Headache and Pain 2021 22:133
    Content type: Research article Published on:

  29. Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment...

    Authors: C Tassorelli, S Bragg, JH Krege, EG Doty, PA Ardayfio, D Ruff, SA Dowsett and T Schwedt
    Citation: The Journal of Headache and Pain 2021 22:132
    Content type: Research article Published on:

  30. Authors: Sara Bottiroli, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli and Grazia Sances
    Citation: The Journal of Headache and Pain 2021 22:131
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2021 22:114

  31. In this study, we aimed to investigate the spontaneous neural activity in the conventional frequency band (0.01−0.08 Hz) and two sub-frequency bands (slow-4: 0.027–0.073 Hz, and slow-5: 0.01–0.027 Hz) in tensi...

    Authors: Shuxian Zhang, Huayun Li, Qinyan Xu, Chao Wang, Xue Li, Jiawei Sun, Yaqi Wang, Tong Sun, Qianqian Wang, Chengcheng Zhang, Jili Wang, Xize Jia and Xihe Sun
    Citation: The Journal of Headache and Pain 2021 22:129
    Content type: Research article Published on:

  32. Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple f...

    Authors: Fenne Vandervorst, Laura Van Deun, Annelies Van Dycke, Koen Paemeleire, Uwe Reuter, Jean Schoenen and Jan Versijpt
    Citation: The Journal of Headache and Pain 2021 22:128
    Content type: Research article Published on:

  33. Migraine sufferers face difficulties getting appropriate care and treatment. Migraine is associated with reduced gray matter volume (GMV) in several brain regions, which could be related to various clinical ch...

    Authors: Shana A.B. Burrowes, Olga Goloubeva, Michael L Keaser, Jennifer A. Haythornthwaite and David A. Seminowicz
    Citation: The Journal of Headache and Pain 2021 22:127
    Content type: Research article Published on:

  34. The MIDAS is the most used questionnaire to evaluate migraine-related disability, but its utility to assess treatment response remains unclear. Our aim was to estimate the MIDAS’ minimal important change (MIC)...

    Authors: Gabriela F. Carvalho, Kerstin Luedtke and Tobias Braun
    Citation: The Journal of Headache and Pain 2021 22:126
    Content type: Short report Published on:

  35. To compare symptoms of clinical androgen deficiency between men with migraine, men with cluster headache and non-headache male controls.

    Authors: Iris E. Verhagen, Roemer B. Brandt, Carlijn M. A. Kruitbosch, Antoinette MaassenVanDenBrink, Rolf Fronczek and Gisela M. Terwindt
    Citation: The Journal of Headache and Pain 2021 22:125
    Content type: Research article Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:135

  36. Migraine has been associated with cardiovascular disease (CVD) events among middle-aged adults. The objective of this study was to determine the risk for ischemic stroke and coronary heart disease (CHD) events...

    Authors: Emily C. McKinley, Christine L. Lay, Robert S. Rosenson, Ligong Chen, Victoria Chia, Lisandro D. Colantonio, Paul Muntner, Robert Urman and Michael E. Farkouh
    Citation: The Journal of Headache and Pain 2021 22:124
    Content type: Research article Published on:

  37. Obesity confers adverse effects to every system in the body including the central nervous system. Obesity is associated with both migraine and idiopathic intracranial hypertension (IIH). The mechanisms underly...

    Authors: Connar Stanley James Westgate, Ida Marchen Egerod Israelsen, Rigmor Højland Jensen and Sajedeh Eftekhari
    Citation: The Journal of Headache and Pain 2021 22:123
    Content type: Review article Published on:

  38. Brain arteriovenous malformations (AVMs) consist of abnormal connections between arteries and veins via an interposing nidus. While hemorrhage is the most common presentation, unruptured AVMs can present with ...

    Authors: Benjamin N Africk, Daniel M Heiferman, Amy W Wozniak, Faraz Behzadi, Matthew S Ballard, Joshua M Chazaro, Brandon M Zsigray, Rachyl M Shanker, Matthew R Reynolds, Douglas E Anderson and Joseph C Serrone
    Citation: The Journal of Headache and Pain 2021 22:122
    Content type: Research article Published on:

  39. Calcitonin gene-related peptide (CGRP) is expressed throughout the body and is a known mediator of migraine, exerting this biological effect through activation of trigeminovascular, meningeal and associated ne...

    Authors: Jason C. Ray, Penelope Allen, Ann Bacsi, Julian J. Bosco, Luke Chen, Michael Eller, Hock Kua, Lyndell L. Lim, Manjit S. Matharu, Mastura Monif, Martin Ruttledge, Richard J. Stark and Elspeth J. Hutton
    Citation: The Journal of Headache and Pain 2021 22:121
    Content type: Case report Published on:

  40. In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their effectiveness in a real-life clinical cohort.

    Authors: Edoardo Caronna, Victor José Gallardo, Alicia Alpuente, Marta Torres-Ferrus and Patricia Pozo-Rosich
    Citation: The Journal of Headache and Pain 2021 22:120
    Content type: Short report Published on:

  41. Migraine is a common neurological disease with extremely debilitating, but fully reversible symptoms. Women suffer from migraine more often than men. It was assumed that fluctuation of oestrogen level during m...

    Authors: Magdalena Kobus, Aneta Sitek, Bogusław Antoszewski, Jacek Rożniecki, Jacek Pełka and Elżbieta Żądzińska
    Citation: The Journal of Headache and Pain 2021 22:119
    Content type: Research article Published on:

  42. Headache is the predominant disabler in idiopathic intracranial hypertension (IIH). The aim was to characterise headache and investigate the association with intracranial pressure.

    Authors: S. P. Mollan, B. R. Wakerley, Z. Alimajstorovic, J. Mitchell, R. Ottridge, A. Yiangou, M. Thaller, A. Gupta, O. Grech, G. Lavery, K. Brock and A. J. Sinclair
    Citation: The Journal of Headache and Pain 2021 22:118
    Content type: Research article Published on:

  43. Recent data suggest that gene expression profiles of peripheral white blood cells can reflect changes in the brain. We aimed to analyze the transcriptome of peripheral blood mononuclear cells (PBMC) and change...

    Authors: Timea Aczél, Tamás Körtési, József Kun, Péter Urbán, Witold Bauer, Róbert Herczeg, Róbert Farkas, Krisztián Kovács, Barna Vásárhelyi, Gellért B. Karvaly, Attila Gyenesei, Bernadett Tuka, János Tajti, László Vécsei, Kata Bölcskei and Zsuzsanna Helyes
    Citation: The Journal of Headache and Pain 2021 22:117
    Content type: Research article Published on:

  44. Authors: Lotte Skytte Krøll, Henriette Edemann Callesen, Louise Ninett Carlsen, Kirsten Birkefoss, Dagmar Beier, Henrik Wulff Christensen, Mette Jensen, Hanna Tómasdóttir, Hanne Würtzen, Christel Vesth Høst and Jakob Møller Hansen
    Citation: The Journal of Headache and Pain 2021 22:116
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2021 22:96

  45. Authors: Anne-Sophie Wattiez, Olivia J. Gaul, Adisa Kuburas, Erik Zorrilla, Jayme S. Waite, Bianca N. Mason, William C. Castonguay, Mengya Wang, Bennett R. Robertson and Andrew F. Russo
    Citation: The Journal of Headache and Pain 2021 22:115
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2021 22:62

  46. Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in ...

    Authors: Sara Bottiroli, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli and Grazia Sances
    Citation: The Journal of Headache and Pain 2021 22:114
    Content type: Research article Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:131

  47. Chronic migraine (CM) and episodic migraine (EM) are associated with substantial headache-related disability, poor quality of life and global societal burden. In this subgroup analysis from the CONQUER study, ...

    Authors: Rose Okonkwo, Antje Tockhorn-Heidenreich, Chad Stroud, Marie-Ange Paget, Manjit S. Matharu and Cristina Tassorelli
    Citation: The Journal of Headache and Pain 2021 22:113
    Content type: Research article Published on:

  48. Trigeminal Neuralgia (TN) is a chronic neurological disease that is strongly associated with neurovascular compression (NVC) of the trigeminal nerve near its root entry zone. The trigeminal nerve at the site o...

    Authors: Judy Alper, Alan C. Seifert, Gaurav Verma, Kuang-Han Huang, Yael Jacob, Ameen Al Qadi, John W. Rutland, Sheetal Patel, Joshua Bederson, Raj K. Shrivastava, Bradley N. Delman and Priti Balchandani
    Citation: The Journal of Headache and Pain 2021 22:112
    Content type: Research article Published on:

  49. Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected pa...

    Authors: Armin Scheffler, Hannah Schenk, Sebastian Wurthmann, Michael Nsaka, Christoph Kleinschnitz, Martin Glas and Dagny Holle
    Citation: The Journal of Headache and Pain 2021 22:111
    Content type: Research article Published on:
Submit manuscript

Official journal of

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.1 - 5-year Impact Factor
    2.002 - SNIP (Source Normalized Impact per Paper)
    1.593 - SJR (SCImago Journal Rank)

    2023 Speed
    3 days submission to first editorial decision for all manuscripts (Median)
    44 days submission to accept (Median)

    2023 Usage
    3,022,321 downloads
    3,296 Altmetric mentions 

  • ISSN: 1129-2377 (electronic)
  • ISSN: 1129-2369 (print)

Related reading

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us